Moomoo AIのまとめ
On February 26, 2024, a Schedule 13G was filed with the United States Securities and Exchange Commission (SEC) by Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, indicating a significant ownership stake in Altimmune, Inc. The filing, which is a requirement for parties owning more than five percent of a company's stock, shows that the entities collectively hold 2,911,937 shares of Altimmune's common stock, representing 5.4% of the company's class of securities. The shares are held with shared voting and dispositive power. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934, which is used by persons who have acquired the securities for investment purposes and not with the intent of changing or influencing the control of the issuer. The principal executive offices of Altimmune, Inc. are located in Gaithersburg, Maryland. The filing also includes a joint filing agreement dated March 4, 2024, confirming the collaborative nature of the filing among the reporting persons.
On February 26, 2024, a Schedule 13G was filed with the United States Securities and Exchange Commission (SEC) by Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, indicating a significant ownership stake in Altimmune, Inc. The filing, which is a requirement for parties owning more than five percent of a company's stock, shows that the entities collectively hold 2,911,937 shares of Altimmune's common stock, representing 5.4% of the company's class of securities. The shares are held with shared voting and dispositive power. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934, which is used by persons who have acquired the securities for investment purposes and not with the intent of changing or influencing the control of the issuer. The principal executive offices of Altimmune, Inc. are located in Gaithersburg, Maryland. The filing also includes a joint filing agreement dated March 4, 2024, confirming the collaborative nature of the filing among the reporting persons.
2024年2月26日、Millennium Management LLC、Millennium Group Management LLC、およびIsrael A. Englanderによって、Altimmune, Inc.の大株主を示すSchedule 13Gが米国証券取引委員会（SEC）に提出されました。この提出は、企業の５％を超える株式を保有する当事者に必要なもので、当該エンティティがAltimmuneの普通株式2,911,937株（同社証券種類の5.4％）を共同で所有していることを示しています。その株は共同で投票および取得権を有しています。この提出は、発行体の支配力を変更または影響を与え...すべて展開
2024年2月26日、Millennium Management LLC、Millennium Group Management LLC、およびIsrael A. Englanderによって、Altimmune, Inc.の大株主を示すSchedule 13Gが米国証券取引委員会（SEC）に提出されました。この提出は、企業の５％を超える株式を保有する当事者に必要なもので、当該エンティティがAltimmuneの普通株式2,911,937株（同社証券種類の5.4％）を共同で所有していることを示しています。その株は共同で投票および取得権を有しています。この提出は、発行体の支配力を変更または影響を与えることを意図せずに証券を取得した人が使用する1934年証券取引法の13d-1（c）ルールに基づいて行われました。Altimmune, Inc.の主要な経営幹部事務所はメリーランド州ゲーザースバーグにあります。また、2024年3月4日に日付を記載した合意共同提出書も提出され、報告者間の協力関係を確認しています。
役に立った
役に立たない
